Empagliflozin and functional aerobic capacity in individuals with increased risk of heart failure: The Empire Prevent Cardiac trial.
Key claim: A 180-day course of empagliflozin did not improve VO2 max, daily physical activity, or quality of life in older adults with overweight or obesity and heart failure risk factors.
Abstract
BACKGROUND: Higher maximal oxygen consumption (VO₂ max) is associated with lower risk of developing heart failure (HF). Empagliflozin improves VOmax in HF with reduced ejection fraction, but the effect on VOmax in individuals at risk of HF remain unknown. OBJECTIVE: This study aimed to evaluate the effect of 180 days treatment with empagliflozin compared to placebo on VOmax, daily physical activity level, and quality of life (QoL) in individuals with overweight or obesity and risk of HF. METHOD: This investigator-initiated, double-blinded, randomized, placebo-controlled, multicenter trial included elderly individuals with body mass index >28 kg/mand at least one additional risk factor for HF, including hypertension, ischemic heart disease, stroke, or chronic kidney disease. Individuals with HF or type 2 diabetes mellitus were excluded. The primary endpoint was the mean difference in change of VOmax. The secondary outcome was objectively measured physical activity level. QoL was an explorative outcome. RESULTS: Among 191 randomized individuals (94 empagliflozin, 97 placebo), 89% had hypertension and 66% ischemic heart disease. At baseline, 69% were male, median age was 68 years, median body mass index 31.9 kg/m², mean left ventricular ejection fraction 65 ± 9%, and mean VO₂ max 18.1 ± 4.3 mL/min/kg. Empagliflozin did not change VOmax with an estimated treatment difference of -0.2 mL/min/kg (97.5% confidence interval -1.2 to 0.8), adjusted P = 1.00. No significant treatment differences were observed for neither daily physical activity nor QoL. CONCLUSIONS: Empagliflozin did not affect VOmax, physical activity level, or QoL in elderly individuals with overweight or obesity and risk of HF.
Why this matters
[human-rct] This trial adds a population- and duration-specific negative result for pharmacologically improving aerobic capacity: empagliflozin did not improve VO2max, daily activity, or quality of life over 180 days in older adults at risk of heart failure without established diabetes or heart failure. [human-rct] It tests a drug’s effect on functional outcomes, not whether raising fitness through exercise causes longer survival.